Navigation Links
Watson Confirms Lo Loestrin® Fe Patent Challenge
Date:5/18/2012

tions in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and Watson's Annual Report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Lo Loestri
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
3. Watson to Acquire Actavis Group for EUR4.25 Billion
4. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
5. Taconic IPAs Annette Watson to present at PCPCC meeting
6. Watson Launches Generic FORTAMET(R)
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
8. Watson Confirms Favorable District Court Ruling in Generic Sanctura XR® Patent Suit
9. Watson Partners With March of Dimes to Help Fight Preterm Birth
10. Watson Confirms NIASPAN(R) Patent Challenge
11. Watson Confirms BYSTOLIC(R) Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the Baird 2015 ... . The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/3/2015)... ... 03, 2015 , ... As a result of the Patient ... health insurance plans, more employers are moving to a self-funded model for pharmacy ... 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s ...
(Date:9/3/2015)... ... September 03, 2015 , ... ProScrub is a set of automated tools ... repeat, and custom speed effects without the use of keyframes. Utilize ProScrub's powerful ... ProScrub tools are perfect complements to energetic video productions. ProScrub is a ...
(Date:9/3/2015)... ... 2015 , ... Mum n Me is pleased to announce the launch of ... that gives maximum protection from sun exposure, wind, bugs, and germs. The Mum n ... assurance by keeping the cover securely in place. The new car seat cover is ...
(Date:9/3/2015)... ... ... cases of prostate cancer are reported each year, along with 27,540 deaths attributed to the ... While only one man in 10,000 will typically get prostate cancer under age 40, the ... American Cancer Society. , Prostate cancer is the second leading cause of ...
(Date:9/3/2015)... ... 2015 , ... The partnership will leverage Fidson’s strong and ... to promote LodonalTM in Nigeria. The distribution will become effective, upon completion of ... the product. , Managing Director, Fidson Healthcare Plc, Dr Fidelis Ayebae, expressed that ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4
... , , Gail McG ... Climate , , WASHINGTON, July 13 ... featured speaker at a National Press Club Luncheon on Tuesday, July 21, 2009. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , ...
... MINNEAPOLIS, July 13 Nonin Medical, Inc., ... clearance for its Model 7600 Regional Oximetry System. Introduced in ... in Milan, Italy, the innovative Model 7600 offers real-time monitoring ... , , Utilizing next-generation near-infrared ...
... WASHINGTON, July 13 The Health Coalition on Liability ... legislative proposals for medical liability reform that they will push ... consideration by Congress. , , ... system in order to provide fair and timely compensation to ...
... 17-year-olds without prescription, company says , MONDAY, July 13 (HealthDay ... contraceptive has been approved by the U.S. Food and Drug ... , The new Plan B One-Step will be available at ... The FDA also said it expanded over-the-counter access to Plan ...
... still transmit virus, but disease odds fall by 30 percent, ... who use condoms regularly can reduce their risk of getting ... The herpes simplex virus 2 (HSV-2) causes genital herpes, which ... that regular condom use reduces the spread of HIV and ...
... Leading hearing system ... their work on Hear the World, a global initiative to raise awareness about the importance ... ... the International Stevie Award for Communications Team of the Year for their work on Hear ...
Cached Medicine News:Health News:American Red Cross President to Address National Press Club Luncheon 2Health News:Nonin Medical Announces FDA Clearance for its Next-Generation Regional Oximetry System 2Health News:Health Coalition Sends Legislative Proposals for Medical Liability Reform to Congress 2Health News:Condoms May Reduce Herpes Risk 2Health News:Condoms May Reduce Herpes Risk 3Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 2Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 3
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
... Plus Sterile Isopropyl Alcohol ... primarily used as a ... administering injections. They are ... AAMI/ANSI/ISO 11137 standards to ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
Medicine Products: